WO2011034462A1 - Combined anti-tuberculosis preparation - Google Patents
Combined anti-tuberculosis preparation Download PDFInfo
- Publication number
- WO2011034462A1 WO2011034462A1 PCT/RU2010/000111 RU2010000111W WO2011034462A1 WO 2011034462 A1 WO2011034462 A1 WO 2011034462A1 RU 2010000111 W RU2010000111 W RU 2010000111W WO 2011034462 A1 WO2011034462 A1 WO 2011034462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tuberculosis
- zinc
- isoniazid
- rifampicin
- pyrazinamide
- Prior art date
Links
- 230000002365 anti-tubercular Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title description 8
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 229960003350 isoniazid Drugs 0.000 claims abstract description 27
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960005206 pyrazinamide Drugs 0.000 claims abstract description 24
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims abstract description 24
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000011701 zinc Substances 0.000 claims abstract description 20
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 20
- 229960001225 rifampicin Drugs 0.000 claims abstract description 17
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 239000007909 solid dosage form Substances 0.000 claims abstract description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 13
- 229960001763 zinc sulfate Drugs 0.000 claims description 13
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 7
- 150000003751 zinc Chemical class 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 29
- 229940079593 drug Drugs 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 11
- 241000699670 Mus sp. Species 0.000 description 22
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 22
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 20
- 210000004072 lung Anatomy 0.000 description 18
- 201000008827 tuberculosis Diseases 0.000 description 17
- 239000003826 tablet Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 9
- KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000004738 parenchymal cell Anatomy 0.000 description 6
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000000224 granular leucocyte Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229940118149 zinc sulfate monohydrate Drugs 0.000 description 4
- RNZCSKGULNFAMC-UHFFFAOYSA-L zinc;hydrogen sulfate;hydroxide Chemical compound O.[Zn+2].[O-]S([O-])(=O)=O RNZCSKGULNFAMC-UHFFFAOYSA-L 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940080313 sodium starch Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000000814 tuberculostatic agent Substances 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 244000026610 Cynodon dactylon var. affinis Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000013539 mentalization-based treatment Methods 0.000 description 2
- 238000013048 microbiological method Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 201000006836 Miliary Tuberculosis Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 229940121383 antituberculosis agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000918 protionamide Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960003231 thioacetazone Drugs 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000005089 vacuolized cytoplasm Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- PVCCISSCNBXSKD-UHFFFAOYSA-N zinc heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn] PVCCISSCNBXSKD-UHFFFAOYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Definitions
- the invention relates to medicine, specifically to combination anti-TB drugs, and can be used in various modes of chemotherapy for tuberculosis.
- the main anti-TB drugs include isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin, which are the most effective and bactericidal drugs on the MBT with the lowest frequency of undesirable effects. It is these drugs that are used to treat newly diagnosed patients with tuberculosis.
- the group of reserve anti-TB drugs is kanamycin (amikacin), capreomycin, protionamide, cycloserine, para-aminasalicylic acid (PASK). These are less effective drugs with a bacteriostatic effect, which are a substitute for the main anti-TB drugs in cases of drug resistance of the office or the appearance of fatal adverse reactions of the main PTP [Mishin V.Yu. Treatment of patients with pulmonary tuberculosis. // Teaching aid for doctors. - M: MGMSU. - 2006. - 120 s].
- Chemotherapy for a tuberculosis patient must necessarily be comprehensive and strictly individual. This includes the choice of a combination of anti-TB drugs, and the determination of the treatment regimen taking into account the regional and individual drug sensitivity of the Office, and the choice of pathogenetic methods aimed at normalizing impaired body functions, reducing the degree of inflammatory reaction, eliminating metabolic and immune disorders, as well as stimulating therapy (Manicheva O .A., Skvortsova L.A., Pavlova M.V., Sapozhnikova N.V., Archakova L.I., Vishnevsky B.I. Bacteriostatic blood activity in patients with respiratory tuberculosis mania. // Mat. VIII Ross Congress of TB doctors. - M. - 2007. - S.
- isoniazid is used as the main and most effective anti-TB drug (Khomenko A.G. Chemotherapy of pulmonary tuberculosis.
- Isoniazid has a high bactericidal effect on mycobacterium tuberculosis, but also has a strong toxic effect. But its main drawback is the rapid development of drug resistance of Mycobacterium tuberculosis, which significantly reduces its effectiveness. Isoniazid resistance of mycobacterium tuberculosis develops in 22.2-37.1% of patients and they become chronic patients [Filatova MS Features of the course and treatment of drug-resistant pulmonary tuberculosis: Abstract. dis. ... cand. medical sciences. - M. - 2004. - 25 s].
- the patient simultaneously receives a combination of anti-TB drugs of different classes.
- a method for the treatment of pulmonary tuberculosis including chemotherapy with combinations of anti-TB drugs based on isoniazid or isoniazid and rifampicin, characterized in that zinc sulfate is also prescribed in a daily dose of 2.30 - 3.50 mg / kg two - three times an oral administration, a course of 21-28 days, which allowed to reduce the duration of chemotherapy due to the pronounced anti-apoptotic effect on T-lymphocytes ..
- the known drugs - analogues have a number of significant drawbacks. So with the course application of the above drugs, a pronounced toxic effect and the occurrence of side effects are observed.
- the mutual influence of the ingredients leads to a significant decrease in the bioavailability of the active principle, which worsens the anti-TB activity of the combination and causes a relapse of the disease, as well as the development of secondary drug resistance of mycobacterium tuberculosis.
- the objective of the present invention is to provide a highly effective combined anti-tuberculosis composition, which has increased antimicrobial activity against tuberculosis mycobacteria and minimal toxic side effects.
- the proposed anti-tuberculosis agent includes a therapeutically effective amount of the active principle, which contains a combination of rifampicin, isoniazid, pyrazinamide, a zinc-containing compound and pharmaceutically acceptable excipients.
- the preferred ratio of the ingredients of the active principle is, wt.h .:
- the composition includes a combination of rifampicin, isoniazid, pyrazinamide and a zinc-containing compound.
- zinc-containing compound zinc salts, more preferably zinc sulfate, are preferably used.
- the objective of the in vitro study was to study the microbiological methods of bacteriostatic and bactericidal activity of the new composition and its individual components with respect to Mycobacterium tuberculosis (MBT) - the laboratory strain H37Rv and clinical strains that are sensitive to PTP.
- MMT Mycobacterium tuberculosis
- the culture of the selected strains of Mycobacterium tuberculosis was grown for 21 days on a solid nutrient medium Levinshtein - Jensen (international standard).
- the growth of mycobacteria in a dense medium was taken into account and recorded after 21, 42, and 70 days of cultivation in an incubator at 37 ° C.
- the control was tubes with cultures of test strains that were not exposed to the studied drugs and their mixtures.
- the minimum inhibitory concentration of individual substances and mixtures was characterized by a significant decrease in the number of colonies in a dense nutrient medium compared to the control.
- the minimum bactericidal concentration was defined as the concentration causing a complete suppression of the growth of mycobacteria in a dense nutrient medium.
- the study of the bacteriostatic and bactericidal concentration of the mechanical mixture of FC preparations, similar in composition to the new composition, for mycobacterium tuberculosis of the laboratory strain H37Rv and clinical strains sensitive to anti-TB drugs also showed its high inhibitory effect at low concentrations.
- the MIC and MBC values in this case are higher - 11.46 ⁇ g / ml and 25.0 ⁇ g / ml, respectively.
- the new composition has clinical, sensitive to mycobacterium tuberculosis anti-TB drugs of strains, high inhibitory effect at a low concentration of 6.25 ⁇ g / ml.
- the bactericidal effect, most desirable when creating new drugs, is observed at its concentration in the nutrient medium in the amount of 18.7 ⁇ g / ml.
- M. tuberculosis strain H37Rv M. tuberculosis strain H37Rv
- mice of the AKR line obtained from vivarium of the Central Scientific Research Institute of Cytology and Genetics, RAMS.
- the weight of the mice is 22-23 grams.
- Mice were infected by the intravenous administration of M. tuberculosis strain H37Rv from the collection of the Pasteur Institute (France) into the lateral tail vein at a dose of 5x106 CFU / mouse.
- MBTs were obtained in the immunogenetics laboratory of the Central Research Institute of Cardiology, Russian Academy of Medical Sciences. Aliquots (1ml) were stored at - 700C. To infect mice, an aliquot was thawed, transferred to a phosphate buffered saline containing 0.025% Tween 80, and adjusted to a concentration of 5x106 CFU / 0.5 ml. To determine the amount of CFU Mycobacteria in the resulting suspension were prepared by a series of serial dilutions and 20 ⁇ l of each dilution was placed dropwise onto a Petri dish with Dubo agar. The cups were cultured at 37 ° C for 14 days to determine the concentration of MB in the infectious material.
- infected mice without treatment (control), infected mice receiving an intragastric composition consisting of isoniazid + rifampicin + pyrazinamide preparations at a dose of 38 mg / kg;
- mice receiving the intragastrically declared composition isoniazid + rifampicin + pyrazinamide + zinc sulfate at a dose of 38 mg / kg;
- mice receiving intragastric isoniazid at a dose of 38 mg / kg.
- test drugs were administered intragastrically, daily (except weekends), for 2 months, two weeks after infection, previously dissolved in water.
- the injection volume was 0.5 ml / mouse.
- CFU colony forming units
- CFU MBT mycobacteria
- the main indicators of resistance of an animal to tuberculosis are the survival time after infection, the ability to control the multiplication of mycobacteria in organs (i.e., the number of mycobacteria, measured in CFU) and the degree of pathological changes in lung tissue.
- mice of the control group that did not receive any drugs the average life expectancy after a lethal dose of infection was 28.2 ⁇ 0.44 days.
- Mice treated with the claimed composition isoniazid + rifampicin + pyrazinamide + zinc sulfate, as well as a combination consisting of drugs isoniazid + rifampicin + pyrazinamide, and only one isoniazid, remained alive at the time of slaughter and the entire experiment.
- the number of CFU of MBT seeded from the lungs of mice treated with isoniazid and the combination consisting of preparations of isoniazid + rifampicin + pyrazinamide was approximately the same.
- 10 times less MBT were seeded than in mice of the above groups.
- mice With intravenous administration of MBT, an exudative-necrotic inflammatory process develops in mice, affecting various parenchymal organs. Untreated animals die from generalized tuberculosis after 1-2 months. By the time of death in the lungs, liver and spleen, plethora, erythrocyte sludge is observed, young and mature forms of PNL (polymorphonuclear leukocytes) are detected in the blood vessels of large and medium caliber. Around the vessels cell infiltrates consisting of mono- and polynuclear cells are formed; the amount of the latter varies in different organs.
- PNL polymorphonuclear leukocytes
- Alveoli bordering with foci are partially or completely filled with edematous fluid, contain fibrin and fragments of destroyed cellular elements.
- the interalveolar septa are thickened due to interstitial edema and infiltration by mono- and polynuclear cells.
- the same cells are defined in the extended loops of the capillary network.
- Animals treated with isoniazid are characterized by a more pronounced infiltration of the interalveolar septa with monocytes and lymphocytes, which can also form small perivascular infiltrates.
- PNL was not found in their composition, as well as in the lumen of blood vessels.
- the new composition is highly therapeutic and that it can be used as an anti-tuberculosis drug.
- the proposed drug is performed in the form of various solid dosage forms - tablets, capsules, granules, powders.
- substances commonly used in the pharmaceutical industry for the production of solid dosage forms can be used, for example, starch, saccharide, cellulose and its derivatives, gelatin, polyvinylpyrrolidone, polyethylene oxide, calcium phosphate, a lubricant, a wetting agent such as sodium lauryl sulfate, esters polyoxyethylene sorbitan and fatty acids (twins), esters of sorbitan and fatty acids (spans), preferably starch, including modified starch, lactose, microcrystalline c llyuloza, natriykroskarboksimetil- cellulose, polyvinylpyrrolidone, lubricant.
- stearic acid and / or its salts examples include calcium stearate, magnesium stearate, zinc stearate, talc, colloidal silicon dioxide, aerosil, polyethylene glycol, hydrogenated vegetable oil, liquid paraffin.
- the new composition may also contain flavors, colorants and / or flavors.
- the preparation is made in the form of a tablet, which may be coated.
- the presence of the latter improves the appearance and organoleptic properties of the dosage form, protects it from mechanical damage.
- the casing is based on, for example, a ready-made mixture of the brand "Opadry brown”.
- a preferred quantity of active ingredient in a single dose is: for rifampicin from 5 mg to 180 mg, more preferably 150 mg, for isoniazid from 5 mg to 150 mg, more preferably 75 mg, for pyrazinamide from 5 mg to 400 mg, more preferably 400 mg, for a zinc-containing compound (in terms of elemental zinc) from 0.75 mg to 4.0 mg, more preferably 4.0 mg, which corresponds to 2.0 mg to 11.0 mg of zinc sulfate monohydrate, more preferably 11, 0 mg zinc sulfate monohydrate or 3.29 mg to 17.6 mg sulfate heptahydrate zinc, more preferably 17.6 mg of zinc sulfate heptahydrate.
- zinc-containing compounds are zinc salts - sulfate, aspartate, hyaluronate, glycerate, picolinate, citrate, acetate, most preferably zinc sulfate is used in the inventive composition.
- zinc sulfate can also be incorporated into the composition in the form of a hydrate, for example heptahydrate or monohydrate, preferably in the form of a monohydrate.
- the preparation of the claimed dosage form can be carried out in accordance with known methods for the manufacture of solid dosage forms, for example, by wet granulation followed by adding a lubricant to the dry granules, molding the final mixture of ingredients to form the dosage form of a given configuration and size, and, if necessary, coating .
- Example 1 Pre-sieved powders of pyrazinamide, isoniazid, corn starch, microcrystalline cellulose with colloidal anhydrous silica is mixed until homogeneous, granulated with pre-prepared corn starch paste and dried.
- the pre-sifted mixture of rifampicin, zinc sulfate monohydrate, sodium starch glucolate, colloidal anhydrous silica with crosscarmellose sodium are mixed with dry granules in a Yumin blender, pre-sieved magnesium stearate and talc are added to it, mixed in a blender for 5 minutes.
- the finished mass is tabletted. Get tablets with an average weight of 950 mg.
- the content of rifampicin in one tablet is 150 mg, isoniazid is 75 mg, pyrazinamide is 400 mg; zinc content (UV spectrometry) is 4.00 mg or in terms of anhydrous zinc sulfate is 9.9 mg; strength is NLT 6 kg
- a film-forming composition is applied to the obtained tablets based on a pre-prepared composition consisting of "Opadry brown 04B56956", isopropyl alcohol, methylene chloride. Layering is carried out until a film of satisfactory thickness is obtained. The resulting tablets with an average weight of 965 mg satisfy the regulatory requirements for a pharmaceutical agent. Disintegration time - 30 minutes.
- Example 2 Pre-sieved powders of pyrazinamide, isoniazid, corn starch, microcrystalline cellulose with colloidal anhydrous silica are mixed until homogeneous, granulated with pre-prepared corn starch paste and dried. A pre-sieved mixture of rifampicin, zinc sulfate monohydrate, sodium starch glucolate, anhydrous colloidal silicon dioxide with sodium crosscarmellose are mixed with dry granules in a Yumin blender, pre-sieved magnesium stearate and talc are added to it, mixed in a blender for 5 minutes. The finished mass is tabletted. Get pills with average weight of 1050 mg.
- the content of rifampicin in one tablet is 180 mg, isoniazid is 150 mg, pyrazinamide is 400 mg, zinc content (UV spectrometry) is 4.00 mg, or in terms of zinc sulfate - 9.9 mg, strength - NLT 6 kg .
- a film-forming composition is applied to the obtained tablets based on a pre-prepared composition consisting of "Opadry brown 04B56956", isopropyl alcohol, methylene chloride. Layering is carried out until a film of satisfactory thickness is obtained. The resulting tablets with an average weight of 1071 mg satisfy the regulatory requirements for a pharmaceutical agent. Disintegration time - 30 minutes.
- Example 3 Pre-sieved powders of pyrazinamide, isoniazid, corn starch, microcrystalline cellulose with colloidal anhydrous silica are mixed until homogeneous, granulated with pre-prepared corn starch paste and dried.
- the pre-sieved mixture of rifampicin, zinc heptahydrate, sodium starch glucolate, anhydrous colloidal silicon dioxide with sodium crosscarmellose is mixed with dry granules in a Yumin blender, pre-sieved magnesium stearate and talc are added to it, mixed in a blender for 5 minutes.
- the finished mass is tabletted. Get tablets with an average weight of 23.8 mg.
- the content of rifampicin in one tablet is 5 mg, isoniazid is 5 mg, pyrazinamide is 5 mg zinc content (UV spectrometry) is 0.75 mg or in terms of anhydrous zinc sulfate is 1.8 mg, strength is NLT 6 kg
- a film-forming composition is applied to the obtained tablets based on a pre-prepared composition consisting of "Opadry brown 04B56956", isopropyl alcohol, methylene chloride. Layering is carried out until a film of satisfactory thickness is obtained. The resulting tablets with an average weight of 24.5 mg satisfy the regulatory requirements for a pharmaceutical agent. Disintegration time - 30 minutes.
- the inventive pharmaceutical composition can be widely used in healthcare as a medicine for the treatment of tuberculosis.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201200397A EA020961B1 (en) | 2009-09-16 | 2010-03-15 | Combined anti-tuberculosis preparation |
UAA201204215A UA104337C2 (en) | 2009-09-16 | 2010-03-15 | Combined antituberculous preparation containing zinc sulphate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009134473 | 2009-09-16 | ||
RU2009134473/15A RU2430724C2 (en) | 2009-09-16 | 2009-09-16 | Coformulated antituberculous drug |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011034462A1 true WO2011034462A1 (en) | 2011-03-24 |
Family
ID=43758871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2010/000111 WO2011034462A1 (en) | 2009-09-16 | 2010-03-15 | Combined anti-tuberculosis preparation |
Country Status (4)
Country | Link |
---|---|
EA (1) | EA020961B1 (en) |
RU (1) | RU2430724C2 (en) |
UA (1) | UA104337C2 (en) |
WO (1) | WO2011034462A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10335374B2 (en) | 2014-12-04 | 2019-07-02 | University System of Georgia, Valdosta State University | Tablet composition for anti-tuberculosis antibiotics |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001095887A1 (en) * | 2000-06-13 | 2001-12-20 | Laboratorios Alcala Farma, S.L. | Solid, orally administered, water-dispersible pharmaceutical form for the treatment of tuberculosis, containing rifampicin, isoniazid, pirazinamide and pyridoxine hydrochloride, method for obtaining and presentation form of said pharmaceutical form |
EP0650728B1 (en) * | 1993-10-29 | 2002-02-27 | Council of Scientific and Industrial Research | Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug |
RU2195937C1 (en) * | 2002-02-06 | 2003-01-10 | НИИ молекулярной медицины ММА им. И.М.Сеченова | Combined antituberculosis preparation (rizobutol) |
RU2253460C1 (en) * | 2004-08-02 | 2005-06-10 | Федеральное государственное образовательное учреждение высшего профессионального образования Чувашский государственный университет им. И.Н. Ульянова | Method for treating pulmonary tuberculosis |
-
2009
- 2009-09-16 RU RU2009134473/15A patent/RU2430724C2/en not_active IP Right Cessation
-
2010
- 2010-03-15 EA EA201200397A patent/EA020961B1/en not_active IP Right Cessation
- 2010-03-15 WO PCT/RU2010/000111 patent/WO2011034462A1/en active Application Filing
- 2010-03-15 UA UAA201204215A patent/UA104337C2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0650728B1 (en) * | 1993-10-29 | 2002-02-27 | Council of Scientific and Industrial Research | Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug |
WO2001095887A1 (en) * | 2000-06-13 | 2001-12-20 | Laboratorios Alcala Farma, S.L. | Solid, orally administered, water-dispersible pharmaceutical form for the treatment of tuberculosis, containing rifampicin, isoniazid, pirazinamide and pyridoxine hydrochloride, method for obtaining and presentation form of said pharmaceutical form |
RU2195937C1 (en) * | 2002-02-06 | 2003-01-10 | НИИ молекулярной медицины ММА им. И.М.Сеченова | Combined antituberculosis preparation (rizobutol) |
RU2253460C1 (en) * | 2004-08-02 | 2005-06-10 | Федеральное государственное образовательное учреждение высшего профессионального образования Чувашский государственный университет им. И.Н. Ульянова | Method for treating pulmonary tuberculosis |
Also Published As
Publication number | Publication date |
---|---|
RU2009134473A (en) | 2011-03-27 |
EA201200397A1 (en) | 2012-08-30 |
RU2430724C2 (en) | 2011-10-10 |
UA104337C2 (en) | 2014-01-27 |
EA020961B1 (en) | 2015-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK170922B1 (en) | Cefaclor formulation with long lasting effect | |
Quinn | The effectiveness, in vitro, of miconazole and keteconazole combined with tissue conditioners in inhibiting the growth of Candida albicans | |
EP1569692B1 (en) | Betaine and salicylic acid compositions | |
JP2022543760A (en) | Dosing Regimens for Oral Complement Factor D Inhibitors | |
KR100424503B1 (en) | Metastasis suppressory agents | |
RU2663289C2 (en) | Phenothiazine derivatives and their use against tuberculosis | |
TWI637743B (en) | Use of compounds for the manufacture of preventive and / or therapeutic agents for radiation injury | |
EP2349280B1 (en) | Methods of treatment of hyperuricemia and associated disease states | |
CN105520934B (en) | Application of michelia lactone dimethylamine | |
JP6642892B2 (en) | Drugs for pulmonary fibrosis including dimethylamino Micheliolide | |
JP2019504024A (en) | Pharmaceutical preparation for the treatment of kidney stones and its production and use | |
CN107334767B (en) | A kind of application of pyridazinone compound in oncotherapy | |
RU2430724C2 (en) | Coformulated antituberculous drug | |
CN113329749A (en) | Combination therapy for the treatment of uveal melanoma | |
RU2468802C2 (en) | Combined antituberculous composition | |
RU2413517C1 (en) | Combined antituberculous composition | |
CN101863876B (en) | Fluoroquinolone comprising 7-(3-amino-4-oximido)-1-piperidyl substitutional group and application of composition thereof | |
RU2478389C2 (en) | Pharmaceutical anti-tuberculosis combined composition | |
CN102614180A (en) | Use of itraconazole in preparation of drug for treating multiple myeloma | |
RU2195937C1 (en) | Combined antituberculosis preparation (rizobutol) | |
CN108392482B (en) | β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury | |
WO2024140295A1 (en) | Pharmaceutical combination for treating tumors and use thereof | |
WO2022145443A1 (en) | Pharmaceutical composition for treating chronic kidney disease | |
RU2283112C1 (en) | Anti-inflammatory medicinal agent | |
CN102844024A (en) | Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10817497 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201200397 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201204215 Country of ref document: UA |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10817497 Country of ref document: EP Kind code of ref document: A1 |